Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Increases Stake in Calando

Premium

Arrowhead Research said this week that it has increased its majority ownership in RNAi drugs developer Calando Pharmaceuticals.

Arrowhead said it exchanged a warrant to purchase approximately 3.9 million shares of its stock for Calando Series A preferred stock with a liquidation preference of approximately $3.9 million.

"The Calando preferred stock is convertible into 2.7 million shares of Calando common stock at the discretion of the holder," Arrowhead said.

The warrants have an exercise price of $0.50 per share and are exercisable beginning March 17, 2011. They expire Sept. 16, 2015.